Michael Fisher

Michael T. Fisher

Senior Principal Scientist
Scientific Strategy & Analysis

Michael Fisher, Ph.D. serves as Senior Principal Scientist in Scientific Strategy & Analysis for Altria Client Services (ALCS) in Richmond, VA. In this role, he leads the science integration for U.S. Smokeless Tobacco Company with a focus on the scientific substantiation and regulatory requirements for potentially reduced harm tobacco products. He is currently focused on providing scientific support to the development of lower risk oral tobacco derived nicotine containing products.

Since joining the company in 2005, he has been active in a variety of scientific disciplines, including epidemiology, survey research, toxicology and risk assessment, agronomics and microbiology. His work supports regulatory submissions to the U.S. Food & Drug Administration and has resulted in several scientific publications. Most recently, in the BMC Harm Reduction Journal, he was the lead author of a publication reviewing smokeless tobacco mortality risks based comprehensive analysis of two contemporary nationally representation longitudinal mortality studies. He has also co-authored studies in the areas of cigarette ingredient toxicology, mitigation of nitrosamine formation in tobacco, health risks associated with dual use of cigarettes and smokeless tobacco and the sensory responses to cigarettes with varying levels of nicotine.

Dr. Fisher holds a Ph.D. in Biology from Virginia Tech and conducted part of his doctoral research at the Max-Planck-Institut für Biologie in Tübingen, Germany. Prior to joining Altria, Dr. Fisher was an NIH funded post-doctoral fellow at the Medical College of Virginia, Department of Pharmacology and Toxicology conducting research in the areas of immune suppression and immunotherapy for cancer treatment.

PhD Biology Virginia Tech, Blacksburg VA 2000

MS Biology Virginia Tech, Blacksburg VA 1997

BA History Virginia Tech, Blacksburg VA 1995